Scarica l'app Stockscreener
31.90
4.26%
-1.42
Dopo l'orario di chiusura:
31.53
-0.37
-1.16%
Precedente Chiudi:
$33.32
Aprire:
$32.5
Volume 24 ore:
2.42M
Relative Volume:
1.66
Capitalizzazione di mercato:
$5.04B
Reddito:
$803.07M
Utile/perdita netta:
$-358.81M
Rapporto P/E:
-13.07
EPS:
-2.44
Flusso di cassa netto:
$-374.21M
1 W Prestazione:
-8.20%
1M Prestazione:
-8.75%
6M Prestazione:
-35.50%
1 anno Prestazione:
-37.93%
Intervallo 1D:
$31.81
$33.77
Intervallo di 1 settimana:
$31.81
$35.31
Portata 52W:
$31.40
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Confronta IONS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
31.90 | 5.04B | 803.07M | -358.81M | -374.21M | -2.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Ripresa | Jefferies | Buy |
| 2024-06-14 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap DownTime to Sell? - MarketBeat
Ionis Pharmaceuticals Says Data Readout From Pelacarsen Study Is Delayed -January 31, 2025 at 01:17 pm EST - Marketscreener.com
Ionis stock slips as Novartis delays heart drug trial (NVS) - Seeking Alpha
SG Americas Securities LLC Raises Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Familial Chylomicronemia Syndrome FDA Approvals, Clinical - openPR
September 19th Options Now Available For Ionis Pharmaceuticals - Nasdaq
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Up 7%Time to Buy? - MarketBeat
FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug - Yahoo Finance
What is Leerink Partnrs’ Forecast for IONS FY2024 Earnings? - Defense World
Spinocerebellar Ataxias Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart
70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - Yahoo Finance
Ionis stock rises on FDA, EMA nod for SMA drug dose increase - MSN
William Blair Brokers Increase Earnings Estimates for IONS - MarketBeat
Biogen/ Ionis Spinraza being reviewed for higher dose (BIIB) - Seeking Alpha
Leerink Partnrs Has Negative Outlook of IONS FY2024 Earnings - MarketBeat
Ionis Pharmaceuticals Insiders Sold US$3.2m Of Shares Suggesting Hesitancy - Simply Wall St
Transthyretin Amyloid Cardiomyopathy Treatment Market - openPR
Assenagon Asset Management S.A. Raises Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Position Boosted by Assenagon Asset Management S.A. - Defense World
Ionis Pharmaceuticals EVP sells $241,628 in stock - MSN
Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock - MSN
Ionis Pharmaceuticals exec sells $144,861 in stock - MSN
Ionis Pharmaceuticals EVP Eric Swayze sells $235,678 in stock - MSN
Ionis Pharmaceuticals CEO Brett Monia sells $1.09 million in stock - MSN
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze Sells 7,154 Shares - MarketBeat
Brett P. Monia Sells 33,445 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharmaceuticals EVP sells $232,407 in stock - MSN
Ionis Pharmaceuticals CFO sells stock worth $290,989 - MSN
Ionis Pharmaceuticals exec sells $144,861 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP sells $232,407 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP sells $213,889 in stock - MSN
Bennett C. Frank of Ionis Pharmaceuticals sells $222,113 in stock - MSN
Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP Eric Swayze sells $235,678 in stock By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals CFO sells stock worth $290,989 By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals EVP sells $241,628 in stock By Investing.com - Investing.com Canada
EVP, Chf Clinical Develop Ofcr Schneider Eugene converted options into 17,372 shares and sold $213,889 worth of shares (6,523 units at $32.79), increasing direct ownership by 23% to 58,508 units (SEC Form 4) - Quantisnow
Director Yang Michael J. converted options into 1,931 shares (SEC Form 4) - Quantisnow
EVP Research Swayze Eric converted options into 19,160 shares and sold $235,678 worth of shares (7,176 units at $32.84), increasing direct ownership by 35% to 45,670 units (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):